Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | −$1.99 | — | $364.25M | +71.2% | −$2.66 |
| Q1 FY26ended Mar 31, 2026 | May 12, 2026 | −$3.25 | — | $311.34M | +126.8% | −$4.27 |
| Q4 FY25ended Dec 31, 2025 | — | −$5.36 | — | $321.08M | +210.8% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$5.08 | — | $287.27M | +362.0% | — |
| Q2 FY25ended Jun 30, 2025 | — | −$1.50 | — | $212.80M | +1353.8% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$2.61 | — | $137.25M | — | — |
| Q4 FY24ended Dec 31, 2024 | — | −$2.71 | — | $103.32M | — | — |
| Q3 FY24ended Sep 30, 2024 | — | −$4.92 | — | $62.18M | — | — |
| Q2 FY24 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Madrigal Pharmaceuticals shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| −$7.10 |
| — |
| $14.64M |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$7.38 | — | — | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$5.67 | — | $0 | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$5.34 | — | — | — | — |